Exploring the scientific underpinnings of investigating safety signals: analytical insights in deciphering drug safety evidence by Tarek A. Hammad, Simon Davis, Salman Afsar

Connect to this object online.

Achieving synchrony: bridging the gap between pharmaceutical companies and regulators on safety labeling updates by Tarek A. Hammad, Sasan Sabrdaran, Jean-Marie Heim

Connect to this object online.

Navigating a transforming landscape: the evolving role of pharmacovigilance physicians in drug development and implications for future challenges and training requirements by Tarek A. Hammad, Salman Afsar, Herve Le-Louet, Herve Le-Louet, Veronique F. Kugener

Connect to this object online.

Aspects to consider in causality assessment of safety signals: broadening the thought process by Tarek A. Hammad, Salman Afsar, Laura B. McAvoy, Hervé Le Louet, Hervé Le Louet

Connect to this object online.

How can patient preferences be used and communicated in the regulatory evaluation of medicinal products? Findings and recommendations from IMI PREFER and call to action by Rosanne Janssens, Liese Barbier, Mireille Muller, Irina Cleemput, Isabelle Stoeckert, Chiara Whichello, Bennett Levitan, Tarek A. Hammad, Charis Girvalaki, Juan-Jose Ventura, Karin Schölin Bywall, Karin Schölin Bywall, Cathy Anne Pinto, Elise Schoefs, Eva G. Katz, Ulrik Kihlbom, Isabelle Huys

Connect to this object online.